The Toxicity Assessment of Chicken Liver-Based Drug Filler Supplemented with Itraconazole

Itraconazole is a systemic antifungal often used for fungal infection treatment in cats. This study aimed to evaluate the safety of chicken liver paste as a drug filler through an acute toxicity test when supplemented with itraconazole. A total of 25 female mice were used and divided into five groups, each consisting of five mice. The control group received chicken liver paste without any itraconazole supplementation. In contrast, the treatment groups were administered chicken liver paste supplemented with itraconazole at 5, 10, 15, and 20 g/kg body weight dosages. Observations were conducted for two weeks. The evaluated parameters included abnormal clinical signs, mortality, body temperature, weight gain, and hematology profile. During the 14 days of observation, no mortality or abnormal clinical signs were observed. Other parameters such as body temperature and weight increase showed no significant difference. Hematology profile including red blood cells (RBC), hemoglobin (HB), hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), red cell distribution width (RDW), thrombocyte (PLT), mean platelet volume (MPV), platelet distribution width (PDW), plateletcrit (PCT), white blood cells (WBC), lymphocytes, monocytes, and granulocytes remained within the standard ranges and showed no significant difference. The present study indicated that chicken liver paste supplemented with itraconazole falls into the practically nontoxic category with an estimated LD50 value exceeding 20 g/kg body weight.